drugset / Trial / NCT03746249
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody in patients with advanced hepatocellular carcinoma (HCC)
Timeline
- Start
- 2018-12-17
- Primary completion
- 2019-08-01
- Completion
- 2019-12-01
Outcome
Outcome not reported
Stopped (Enrollment): “No participants enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |